First author [ref.] | Country | Type of study | Adalimumab | Etanercept | Infliximab | Comments |
Wallis 12 | USA | Cases voluntarily reported to US FDA | IR 28/100000 | IR 54/100000 | Etanercept versus infliximab p<0.0001 | |
Brassard 105 | Canada | Search of a large pharmacy prescription database | RR 1.2 (0.9–1.8) | RR 1.6 (1.0–2.6) | ||
Gomez-Reino 14 | Spain | Data from registry | IR 176/100000 | IR 114/100000 | IR 383/100000 | p = ns, wide confidence interval |
Tubach 106 | France | Data from registry | IR 215/100000 | IR 9.3/100000 | IR 187.5/100000 | SIR 29.3 for adalimumabSIR 1.8 for etanerceptSIR 18.6 for infliximab.p<0.0001 |
Fonseca 107 | Portugal | Data from registry | 4 cases/171 patients | 1 case/333 patients | 8 cases/456 patients | Exposure is not provided |
US FDA: US Food and Drug Administration; IR: incidence rate; RR: adjusted rate ratio; ns: nonsignificant; SIR: standardised incidence ratio.